NuvOx Pharma’s patented drug platform will treat cancer, stroke, heart attack and other diseases when oxygen deprivation is a contributing factor.
NuvOx’s drug, NVX-108, increases tissue oxygenation. We are in Phase IB clinical trials to treat brain tumors in cooperation with radiation (RT). Brain tumors are hypoxic and NVX-108 improves response to RT. The market potential in cancer can be expanded to $1.4 billion by treating other tumor types. Other applications: stroke (83% decrease in brain damage), heart attack, hemorrhagic shock, traumatic brain injury and sickle cell crisis.